The Global Market for Sleep-Wake Disorders, 2005-2012: Trends, Opportunities, and Insights in a High-Value CNS Therapy Area

Executive Summary

The global market for sleep-wake disorders is worth an estimated US$4.3 billion in 2005 and is forecast to increase 158% to US$11 billion by 2012. Future high growth is anticipated based on the enlarging global markets for insomnia, excessive daytime sleepiness, shift-work sleep disorder, sleep apnoea, and restless legs syndrome.

Furthermore, new therapies in the pipeline that provide complete sleep solutions to patients with impaired sleep-wake rhythms or drugs that improve wakefulness in occupational settings are expected to expand the market considerably in the medium term. Cephalon’s trailblazing in wake-promotion with Provigil, for example, has created a major high growth market sector due to expanded indications into sleep apnoea and shift-work sleep disorder. One of the immediate challenges in the insomnia market is short-term saturation - in the past year, three new products were approved, namely Ambien CR, Lunesta, and

Rozerem, with up to four further drugs expected to be approved and launched over the next 18 months including Indiplon, Gaboxadol, Doxepin, and Posidorm. In view of expanded product choice companies will need to adopt aggressive marketing approaches and utilize key therapeutic differentiators to claim market share for their products. However, the majority of sleep-wake disorders are underdiagnosed or misdiagnosed which indicates a significant market opportunity for manufacturers to redefine marketing strategies to optimize revenues for their products.

In this report, The Global Market for Sleep-Wake Disorders, 2005-2012: Trends, Opportunities, and Insights in a High-Value CNS Therapy Area, the reader will be introduced to an expanding specialty pharmaceutical market segment that is expected to more than double in value by 2012. The scope of the report comprises up-to-date coverage of epidemiological, aetiological, and therapeutic data related to sleep-wake disorders. Market insights and commercial opportunities are acquired through sector analysis of marketed and newly launched products, pipeline drugs, and company activities, in addition to comment on strategic and commercial issues that may affect product positioning and revenue optimization. The report also discusses key prospects that have the potential to become high revenue-earning products over the next decade.

Therapy area forecasting and illustrative comparative sales data is also presented to gain insight into leading products with sales estimates to 2012. Forecasting to 2020 is also detailed to enable the reader to make key assumptions about future markets and to enable the data to be utilized for proprietary predictive market modelling.